Keryx Biopharma (KERX) Well-Positioned for Zerenex Approval in 2014 - Roth Capital
Tweet Send to a Friend
Roth Capital reiterates its Buy rating and $28 price target on Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) following the pharma's presentation ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
